DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Phase 1

Recruiting

Conditions: Hepatic Impairment
Healthy Volunteers

Interventions: Drug: Repotrectinib

First Posted Date: 2024-04-08

Last Posted Date: 2024-07-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT06352528

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Local Institution - 0005, Orlando, Florida, United States
🇺🇸
Local Institution - 0006, Miami Lakes, Florida, United States

and more 3 locations

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Active, not recruiting

Conditions: Advanced Renal Cell Carcinoma (aRCC)

Interventions: Combination Product: Pembrolizumab + Lenvatinib combination therapy
Combination Product: Nivolumab + Ipilimumab combination therapy

First Posted Date: 2024-04-03

Last Posted Date: 2024-08-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 327

Registration Number: NCT06345183

Locations: 🇺🇸
Cardinal Health, Dublin, Ohio, United States

Real-World Effectiveness of Mavacamten in Canada

Not yet recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions: Drug: Mavacamten

First Posted Date: 2024-03-29

Last Posted Date: 2024-03-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT06338202

Locations: 🇨🇦
London Health Science Centre (LHSC), London, Ontario, Canada

Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in Japan

Active, not recruiting

Conditions: Lower-risk Myelodysplastic Syndromes

Interventions: Procedure: Red blood cell transfusion

First Posted Date: 2024-03-07

Last Posted Date: 2024-03-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 300

Registration Number: NCT06298643

Locations: 🇯🇵
Mebix, Inc, Tokyo, Minato-ku, Japan

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

Phase 2

Recruiting

Conditions: Alzheimer Disease, Early Onset

Interventions: Other: Placebo
Drug: BMS-986446

First Posted Date: 2024-02-20

Last Posted Date: 2025-05-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 310

Registration Number: NCT06268886

Locations: 🇯🇵
Hatsuta Neurology Clinic, Hirakata-Shi, Osaka, Japan
🇯🇵
Tominaga Clinic, Osaka-shi, Osaka, Japan
🇯🇵
Memory Clinic Ochanomizu, Bunkyo-Ku, Tokyo, Japan

and more 200 locations

Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Recruiting

Conditions: Moderate-to-severe Plaque Psoriasis

Interventions: Drug: Deucravacitinib

First Posted Date: 2024-02-14

Last Posted Date: 2024-11-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 505

Registration Number: NCT06258668

Locations: 🇰🇷
Local Institution - 0001, Seoul, Korea, Republic of
🇰🇷
Novotech Laboratory Korea Co., Ltd., Seoul, Korea, Republic of

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase 3

Active, not recruiting

Conditions: Cardiomyopathy, Hypertrophic

Interventions: Drug: Placebo
Drug: Mavacamten

First Posted Date: 2024-02-12

Last Posted Date: 2025-05-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT06253221

Locations: 🇺🇸
Local Institution - 0017, Birmingham, Alabama, United States
🇺🇸
Local Institution - 0050, Phoenix, Arizona, United States
🇺🇸
Local Institution - 0032, Los Angeles, California, United States

and more 44 locations

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

Phase 1

Active, not recruiting

Conditions: Dermatitis, Atopic

Interventions: Drug: BMS-986326
Other: Placebo

First Posted Date: 2024-02-08

Last Posted Date: 2025-05-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 54

Registration Number: NCT06248814

Locations: 🇨🇿
Local Institution - 0004, Praha, PR, Czechia
🇨🇿
Local Institution - 0009, Pardubice, Czechia
🇫🇷
Local Institution - 0006, Clermont-Ferrand, France

and more 10 locations

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

First Posted Date: 2024-01-18

Last Posted Date: 2024-03-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT06211179

Locations: 🇺🇸
Local Institution - 0001, San Antonio, Texas, United States

A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan

Recruiting

Conditions: Hypertrophic Cardiomyopathy

Interventions: Other: Quality of life assessment

First Posted Date: 2023-12-26

Last Posted Date: 2024-05-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 470

Registration Number: NCT06181617

Locations: 🇯🇵
Mebix. Inc, Minato-ku, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy